等待开盘 04-02 09:30:00 美东时间
0.000
0.00%
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
03-19 21:37
Mereo BioPharma reported its financial results for 2025, focusing on advancements in setrusumab, alvelestat, and vantictumab. Setrusumab showed significant bone mineral density improvements in Phase 3 studies, though missed primary endpoints. Alvelestat's Phase 3 preparation is progressing, and vantictumab is set to begin a Phase 2 trial. The company ended 2025 with $41 million in cash, providing runway into mid-2027. Key programs are advancing, ...
03-19 12:30
Berger Montague files securities fraud class action against Mereo BioPharma Group plc A securities fraud class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who bought the company’s American Depositary Shares between June 5, 2023 and December 26, 2025. The co
03-02 22:37
Rosen Law Firm Urges Mereo BioPharma ADS Investors to Join Securities Class Action by April 6, 2026 A securities class action has been filed involving Mereo BioPharma Group plc over alleged misstatements and omissions tied to expectations for the Phase 3 ORBIT and COSMIC studies of setrusumab in ost
02-20 06:48
The latest announcement is out from Mereo Biopharma Group Plc ( ($MREO) ). On F...
02-18 07:11
(来源:抗体圈) FierceBiotech每年梳理年度临床实验失败案例。2025年的这份榜单依旧偏向行业头部药企,也反映出一个现实,绝大多数高风险的中晚期...
02-13 12:22
今日重点评级关注:Guggenheim:维持MBX Biosciences"买入"评级,目标价从77美元升至88美元;摩根士丹利:维持DraftKings"超配"评级,目标价从50美元升至53美元
01-20 10:26
双重利好催化!娱乐集团TryHard单日狂升138%;Moderna股价大涨17%,业绩指引超预期,预计2026年实现10%收入增长>>
01-14 14:20
今日重点评级关注:HC Wainwright & Co.:维持NioCorp Developments"买入"评级,目标价从9.5美元升至11.25美元;摩根士丹利:维持Chewy"超配"评级,目标价从48美元升至51美元
01-14 11:25
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-13 20:48